{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:08:55Z","timestamp":1791648535822,"version":"4.3.4"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMJ Case Reports"],"abstract":"<jats:p>To describe the case of a patient who had been receiving abatacept, a T-cell costimulatory molecule blocker for rheumatoid arthritis, and developed an acute encephalomyelitis associated with reactivation of the varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV). A 61-year-old woman receiving abatacept therapy for rheumatoid arthritis developed a disturbance of consciousness. MRI indicated multifocal parenchymal lesions in the brainstem, supratentorial areas and cervical spinal cord. Although steroid therapy significantly improved the neurological symptoms and MRI findings, the patient died of sepsis aggravated by coinfection with a fungal infection. Retrospectively, a PCR assay revealed continued systemic reactivation of VZV, EBV and CMV. Acute encephalomyelitis may be associated with VZV EBV and CMV reactivation during abatacept therapy. Clinicians must be aware of the possibility of acute encephalomyelitis associated with herpes virus reactivation during abatacept therapy for rheumatoid arthritis.<\/jats:p>","DOI":"10.1136\/bcr-2013-009731","type":"journal-article","created":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T01:52:36Z","timestamp":1368150756000},"page":"bcr2013009731","source":"Crossref","is-referenced-by-count":9,"title":["Acute encephalomyelitis with multiple herpes viral reactivations during abatacept therapy"],"prefix":"10.1136","volume":"2013","author":[{"given":"Hideto","family":"Nakajima","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Osaka Medical College I, Takatsuki, Japan"},{"name":"Department of Internal Medicine, Seikeikai Hospital, Sakai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayami","family":"Takayama","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seikeikai Hospital, Sakai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takumi","family":"Ito","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seikeikai Hospital, Sakai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsushi","family":"Yoshikawa","sequence":"additional","affiliation":[{"name":"Departments of Pediatrics, Fujita Health University School of Medicine, Aichi, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2013,5,9]]},"reference":[{"key":"2025082800110500000_2013.may09_1.bcr2013009731.1","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1681\/ASN.V132559","article-title":"The role of novel T cell costimulatory pathways in autoimmunity and transplantation","volume":"2013","author":"Yamada","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.2","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1046\/j.1365-2567.1999.00888.x","article-title":"Interaction of CTLA-4 (CD152) with CD80 or CD86 inhibits human T-cell activation","volume":"2013","author":"Vandenborre","year":"1999","journal-title":"Immunology"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1440-1711.1999.00795.x","article-title":"The role of CTLA-4 in the regulation of T cell immune responses","volume":"2013","author":"McCoy","year":"1999","journal-title":"Immunol Cell Biol"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.4","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1093\/rheumatology\/keq287","article-title":"Abatacept treatment for rheumatoid arthritis","volume":"2013","author":"Schiff","year":"2011","journal-title":"Rheumatology"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.5","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.semarthrit.2008.05.002","article-title":"Serum immunoglobulins and risk of infection: how low can you go?","volume":"2013","author":"Furst","year":"2009","journal-title":"Semin Arthritis Rheum"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.6","first-page":"327","article-title":"Infections during tumor necrosis factor-alpha blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients","volume":"2013","author":"Salliot","year":"2007","journal-title":"Rheumatology"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.7","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1001\/jama.295.19.2275","article-title":"Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials","volume":"2013","author":"Bongartz","year":"2006","journal-title":"JAMA"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.8","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1136\/gut.2006.093294","article-title":"Fatal aseptic meningoencephalitis following infliximab treatment for inflammatory bowel disease","volume":"2013","author":"Quispel","year":"2006","journal-title":"Gut"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.9","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1086\/605498","article-title":"Herpes simplex encephalitis during treatment with tumor necrosis factor-alpha inhibitors","volume":"2013","author":"Bradford","year":"2009","journal-title":"Clin Infect Dis"},{"key":"2025082800110500000_2013.may09_1.bcr2013009731.10","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MAJ.0b013e31822b7bb8","article-title":"Neurological deficits during treatment with tumor necrosis factor-alpha antagonists","volume":"2013","author":"Nozaki","year":"2011","journal-title":"Am J Med Sci"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-009731","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:11:14Z","timestamp":1756365074000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-009731"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,9]]},"references-count":10,"alternative-id":["10.1136\/bcr-2013-009731"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-009731","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,9]]}}}